Generic Viberzi Availability

Last updated on Jan 11, 2023.

Viberzi is a brand name of eluxadoline, approved by the FDA in the following formulation(s):

VIBERZI (eluxadoline - tablet;oral)

Manufacturer: ALLERGAN HOLDINGS
Approval date: May 27, 2015
Strength(s): 75MG ^[RLD], 100MG ^[RLD]

Has a generic version of Viberzi been approved?

No. There is currently no therapeutically equivalent version of Viberzi available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Viberzi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Opioid receptor modulator dosage formulations
Patent 10,188,632
Issued: January 29, 2019
Assignee(s): Allergan Holdings Unlimited Company
Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
Patent expiration dates:
- March 14, 2033
  ✓
  Drug product
Compounds as opioid receptor modulators
Patent 10,213,415
Issued: February 26, 2019
Assignee(s): Janssen Pharmaceutica NV
The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
Patent expiration dates:
- March 14, 2025
  ✓
  Patent use: TREATMENT OF PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
  ✓
  Drug substance
Patent 11,007,179
Patent expiration dates:
- March 14, 2033
  ✓
  Drug product
Patent 11,090,291
Patent expiration dates:
- March 14, 2033
  ✓
  Drug product
Patent 11,160,792
Patent expiration dates:
- March 14, 2033
  ✓
  Drug product
Patent 11,229,627
Patent expiration dates:
- March 14, 2033
  ✓
  Drug product
Patent 11,311,516
Patent expiration dates:
- March 14, 2033
  ✓
  Drug product
Patent 11,484,527
Patent expiration dates:
- March 14, 2033
  ✓
  Patent use: REDUCTION OF THE FREQUENCY OF ABDOMINAL PAIN AND DIARRHEA, IN AN INFLAMMATORY BOWEL DISEASE WITH DIARRHEA (IBS-D) PATIENT, WITH ELUXADOLINE TWICE DAILY WITH FOOD
Compounds as opioid receptor modulators
Patent 7,741,356
Issued: June 22, 2010
Inventor(s): Breslin; Henry J. & Cai; Chaozhong & He; Wei & Kavash; Robert W.
Assignee(s): Janssen Pharmaceutica N.V.
The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
Patent expiration dates:
- May 27, 2029
  ✓
  Drug substance
  ✓
  Drug product
Compounds as opioid receptor modulators
Patent 7,786,158
Issued: August 31, 2010
Inventor(s): Breslin; Henry J. & Cai; Chaozhong & He; Wei & Kavash; Robert W.
Assignee(s): Janssen Pharmaceutica N.V.
The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
Patent expiration dates:
- March 14, 2025
  ✓
  Drug substance
Compounds as opioid receptor modulators
Patent 8,344,011
Issued: January 1, 2013
Inventor(s): Breslin; Henry J. & Cai; Chaozhong & He; Wei & Kavash; Robert W.
Assignee(s): Janssen Pharmaceutica, N.V.
The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
Patent expiration dates:
- March 14, 2025
  ✓
  Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
Compounds as opioid receptor modulators
Patent 8,609,709
Issued: December 17, 2013
Assignee(s): Janssen Pharmaceutica, N. V.
The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
Patent expiration dates:
- March 14, 2025
  ✓
  Drug substance
Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Patent 8,691,860
Issued: April 8, 2014
Assignee(s): Furiex Pharmaceuticals, Inc.
The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.
Patent expiration dates:
- July 7, 2028
  ✓
  Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
  ✓
  Drug substance
Compounds as opioid receptor modulators
Patent 8,772,325
Issued: July 8, 2014
Assignee(s): Janssen Pharmaceutica, N.V.
The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
Patent expiration dates:
- March 14, 2025
  ✓
  Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Patent 9,115,091
Issued: August 25, 2015
Assignee(s): FURIEX PHARMACEUTICALS, INC.
The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.
Patent expiration dates:
- July 7, 2028
  ✓
  Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
  ✓
  Drug substance
  ✓
  Drug product
Compounds as opioid receptor modulators
Patent 9,205,076
Issued: December 8, 2015
Assignee(s): Janssen Pharmaceutica, N.V.
The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
Patent expiration dates:
- March 14, 2025
  ✓
  Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Patent 9,364,489
Issued: June 14, 2016
Assignee(s): Forest Tosara Limited
The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.
Patent expiration dates:
- July 7, 2028
  ✓
  Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
Opioid receptor modulator dosage formulations
Patent 9,675,587
Issued: June 13, 2017
Assignee(s): Allergan Holdings Unlimited Company
Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
Patent expiration dates:
- March 14, 2033
  ✓
  Drug product
Compounds as opioid receptor modulators
Patent 9,700,542
Issued: July 11, 2017
Assignee(s): Janssen Pharmaceutica NV
The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
Patent expiration dates:
- March 14, 2025
  ✓
  Drug product
Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Patent 9,789,125
Issued: October 17, 2017
Assignee(s): Allergan Holdings Unlimited Company
The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.
Patent expiration dates:
- July 7, 2028
  ✓
  Patent use: TREATMENT OF PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
  ✓
  Drug product
- July 7, 2028
  ✓
  Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
  ✓
  Drug product

More about Viberzi (eluxadoline)

Patient resources

Professional resources

Related treatment guides

Irritable Bowel Syndrome with Diarrhea

Glossary

Term	Definition
Drug Patent	A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity	Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD	A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Some potential for abuse 4

Approval History Drug history at FDA

User Reviews & Ratings

6.7 / 10

216 Reviews

Images

Viberzi 75 mg (FX75)